| [1] |
Peters-Golden M, Henderson WR Jr. Leukotrienes[J]. N Engl J Med, 2007, 357(18): 1841-1854.
|
| [2] |
Bateman ED, Hurd SS, Barnes PJ, et al. Global strategy for asthma management and prevention: GINA executive summary[J]. Eur Respir J, 2008, 31(1): 143-178.
|
| [3] |
Rabinovitch N. Urinary leukotriene E4 as a biomarker of exposure, susceptibility and risk in asthma[J]. Immunol Allergy Clin North Am, 2012, 32(3): 433-445.
|
| [4] |
Peters-Golden M, Sampson AP. Cysteinyl leukotriene interactions with other mediators and with glucocorticosteroids during airway inflammation[J]. J Allergy Clin Immunol, 2003, 111(Suppl 1): S37-S42; discussion S43-S48.
|
| [5] |
Liu M, Yokomizo T. The role of leukotrienes in allergic diseases[J]. Allergol Int, 2015, 64(1): 17-26.
|
| [6] |
Woszczek G, Chen LY, Alsaaty S, et al. Concentration-dependent noncysteinyl leukotriene type 1 receptor-mediated inhibitory activity of leukotriene receptor antagonists[J]. J Immunol, 2010, 184(4): 2219-2225.
|
| [7] |
Anderson R, Theron AJ, Gravett CM, et al. Montelukast inhibits neutrophil pro-inflammatory activity by a cyclic AMP-dependent mechanism[J]. Br J Pharmacol, 2009, 156(1): 105-115.
|
| [8] |
中华医学会儿科学分会呼吸学组. 白三烯受体拮抗剂在儿童常见呼吸系统疾病中的临床应用专家共识[J]. 中华实用儿科临床杂志， 2016, 31(13)：973-977.
|
| [9] |
Bisgaard H, Skoner D, Boza ML, et al. Safety and tolerability of montelukast in placebo-controlled pediatric studies and their open-label extensions[J]. Pediatr Pulmonol, 2009, 44(6): 568-579.
|
| [10] |
Sarkar M, Koren G, Kalra S, et al. Montelukast use during pregnancy: a multicentre, prospective, comparative study of infant outcomes[J]. Eur J Clin Pharmacol, 2009, 65(12): 1259-1264.
|
| [11] |
Chan AL, Juarez MM, Gidwani N, et al. Management of critical asthma syndrome during pregnancy[J]. Clin Rev Allergy Immunol, 2015, 48(1): 45-53.
|
| [12] |
Lim A, Stewart K, König K, et al. Systematic review of the safety of regular preventive asthma medications during pregnancy[J]. Ann Pharmacother, 2011, 45(7-8): 931-945.
|
| [13] |
Hung CH. Role of leukotriene receptor antagonists in asthma[J]. Pediatr Neonatol, 2012, 53(4): 219-220.
|
| [14] |
Bérubé D, Djandji M, Sampalis JS, et al. Effectiveness of montelukast administered as monotherapy or in combination with inhaled corticosteroid in pediatric patients with uncontrolled asthma: a prospective cohort study[J]. Allergy Asthma Clin Immunol, 2014, 10(1): 21.
|
| [15] |
Kuo CH, Yang SN, Kuo HF, et al. Cysteinyl leukotriene receptor antagonist epigenetically modulates cytokine expression and maturation of human myeloid dendritic cells[J]. Pulm Pharmacol Ther, 2016, 39: 28-37.
|
| [16] |
Tsai MJ, Wu PH, Sheu CC, et al. Cysteinyl leukotriene receptor antagonists decrease cancer risk in asthma patients[J]. Sci Rep, 2016, 6: 23979.
|
| [17] |
中华医学会儿科学分会呼吸学组. 儿童支气管哮喘诊断与防治指南(2016年版)[J]. 中华儿科杂志，2016, 54(3): 167-181.
|
| [18] |
陈秋芳， 张海邻， 余刚， 等. 呼吸道合胞病毒毛细支气管炎患儿炎症递质的变化[J]．临床儿科杂志， 2014, 32(2): 115-117.
|
| [19] |
Oh JW, Shin SA, Lee HB. Urine leukotriene E and eosinophil cationic protein in nasopharyngeal aspiration from young wheezy children[J]. Pediatr Allergy Immunol, 2005, 16(5): 416-421.
|
| [20] |
李洁， 潘家华. 孟鲁司特对毛细支气管炎患儿白三烯水平的影响[J]. 中国当代儿科杂志， 2015, 17(10): 1062-1065.
|
| [21] |
Kearns GL, Lu S, Maganti L, et al. Pharmacokinetics and safety of montelukast oral granules in children 1 to 3 months of age with bronchiolitis[J]. J Clin Pharmacol, 2008, 48(4): 502-511.
|
| [22] |
Lopez-Campos JL, Calero-Acuña C, Lopez-Ramirez C, et al. Implications of the inflammatory response for the identification of biomarkers of chronic obstructive pulmonary disease[J]. Biomark Med, 2016, 10(2): 109-122.
|
| [23] |
Tufvesson E, Ekberg M, Bjermer L. Inflammatory biomarkers in sputum predict COPD exacerbations[J]. Lung, 2013, 191(4): 413-416.
|
| [24] |
Rubinstein I, Kumar B, Schriever C. Long-term montelukast therapy in moderate to severe COPD: a preliminary observation[J]. Respir Med, 2004, 98(2): 134-138.
|
| [25] |
雷震， 左莹. 孟鲁司特治疗慢性阻塞性肺疾病急性加重期80例疗效分析[J]. 实用药物与临床，2012，15(6): 342-343.
|
| [26] |
Abdel Kawy HS. Montelukast versus dexamethasone treatment in a guinea pig model of chronic pulmonary neutrophilic inflammation[J]. COPD, 2016, 13(4): 455-463.
|
| [27] |
Lee JH, Kim HJ, Kim YH. The effectiveness of anti-leukotriene agents in patients with COPD: a systemic review with Meta-analysis[J]. Lung, 2015, 193(4): 477-486.
|
| [28] |
Shahzad T, Radajewski S, Chao CM, et al. Pathogenesis of bronchopulmonary dysplasia: when inflammation meets organ development[J]. Mol Cell Pediatr, 2016, 3(1): 23.
|
| [29] |
Peters-Golden M, Gleason MM, Togias A. Cysteinyl leukotrienes: multi-functional mediators in allergic rhinitis[J]. Clin Exp Allergy, 2006, 36(6): 689-703.
|
| [30] |
金蕊， 卢红艳， 罗妍妍， 等. 尿半胱氨酸白三烯E4诊断支气管肺发育不良的临床评价[J]. 中华儿科杂志， 2016, 54(9): 703-707.
|
| [31] |
Peters-Golden M, Gleason MM, Togias A. Cysteinyl leukotrienes: multi-functional mediators in allergic rhinitis[J]. Clin Exp Allergy, 2006, 36(6): 689-703.
|
| [32] |
Rupprecht T, Rupprecht C, Harms D, et al. Leukotriene receptor blockade as a life-saving treatment in severe bronchopulmonary dysplasia[J]. Respiration, 2014, 88(4): 285-290.
|
| [33] |
Kim SB, Lee JH, Lee J, et al. The efficacy and safety of montelukast sodium in the prevention of bronchopulmonary dysplasia[J]. Korean J Pediatr, 2015, 58(9): 347-353.
|
| [34] |
Auner B, Geiger EV, Henrich D, et al. Circulating leukotriene B4 identifies respiratory complications after trauma[J]. Mediators Inflamm, 2012, 2012: 536156.
|
| [35] |
刘涛， 任成山. 炎症介质在急性肺损伤/急性呼吸窘迫综合征发病机制中的作用[J/CD]. 中华肺部疾病杂志(电子版), 2013, 6(3): 60-63，70.
|
| [36] |
Reiss LK, Uhlig U, Uhlig S. Models and mechanisms of acute lung injury caused by direct insults[J]. Eur J Cell Biol, 2012, 91(6-7): 590-601.
|
| [37] |
Bhatia M, Moochhala S. Role of inflammatory mediators in the pathophysiology of acute respiratory distress syndrome[J]. J Pathol, 2004, 202(2): 145-156.
|
| [38] |
Bitencourt CS, Bessi VL, Huynh DN, et al. Cooperative role of endogenous leucotrienes and platelet-activating factor in ischaemia-reperfusion-mediated tissue injury[J]. J Cell Mol Med, 2013, 17(12): 1554-1565.
|
| [39] |
Tsubomatsu C, Shintani T, Abe A, et al. Diagnosis and treatment of obstructive sleep apnea syndrome in children[J]. Adv Otorhinolaryngol, 2016, 77: 105-111.
|
| [40] |
Tsaoussoglou M, Lianou L, Maragozidis P, et al. Cysteinyl leukotriene receptors in tonsillar B- and T-lymphocytes from children with obstructive sleep apnea[J]. Sleep Med, 2012, 13(7): 879-885.
|
| [41] |
Shen Y, Xu Z, Huang Z, et al. Increased cysteinyl leukotriene concentration and receptor expression in tonsillar tissues of Chinese children with sleep-disordered breathing[J]. Int Immunopharmacol, 2012, 13(4): 371-376.
|
| [42] |
梁敏， 朱美华， 王志坚， 等. 白三烯B4与儿童腺样体肥大的关系研究[J]. 中国妇幼保健， 2015, 30(17)：2765-2767.
|
| [43] |
Shokouhi F, Meymaneh Jahromi A, Majidi MR, et al. Montelukast in adenoid hypertrophy: its effect on size and symptoms[J]. Iran J Otorhinolaryngol, 2015, 27(83): 443-448.
|
| [44] |
Goldbart AD, Greenberg-Dotan S, Tal A. Montelukast for children with obstructive sleep apnea: a double-blind, placebo-controlled study[J]. Pediatrics, 2012, 130(3): e575-e580.
|
| [45] |
Kheirandish L, Goldbart AD, Gozal D. Intranasal steroids and oral leukotriene modifier therapy in residual sleep-disordered breathing after tonsillectomy and adenoidectomy in children[J]. Pediatrics, 2006, 117(1): e61-e66.
|
| [46] |
宁静， 徐勇胜， 董汉权. 孟鲁司特治疗肺炎支原体感染临床效果及对白三烯水平的影响[J]．中华医院感染学杂志， 2014, 24(6)：1375-1377.
|
| [47] |
鞠善良， 李超， 王在义. N-乙酰半胱氨酸联合小剂量糖皮质激素治疗特发性肺间质纤维化疗效的Meta分析[J]. 中国循证医学杂志， 2013, 13(6)：717-722.
|